Fiera Capital Has Decreased Splunk (SPLK) Holding; Oncomed Pharmaceuticals Has 0.71 Sentiment

January 14, 2018 - By Peter Erickson

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $116.22 million. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

Fiera Capital Corp decreased Splunk Inc (SPLK) stake by 1.69% reported in 2017Q3 SEC filing. Fiera Capital Corp sold 9,699 shares as Splunk Inc (SPLK)’s stock rose 2.42%. The Fiera Capital Corp holds 563,107 shares with $37.41M value, down from 572,806 last quarter. Splunk Inc now has $12.68B valuation. The stock increased 0.21% or $0.19 during the last trading session, reaching $89.64. About 1.41M shares traded. Splunk Inc. (NASDAQ:SPLK) has risen 30.53% since January 14, 2017 and is uptrending. It has outperformed by 13.83% the S&P500.

The stock increased 0.33% or $0.01 during the last trading session, reaching $3.07. About 371,085 shares traded or 82.85% up from the average. OncoMed Pharmaceuticals, Inc. (OMED) has declined 70.06% since January 14, 2017 and is downtrending. It has underperformed by 86.76% the S&P500.

Analysts await OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report earnings on March, 14. They expect $-0.31 earnings per share, up 55.71% or $0.39 from last year’s $-0.7 per share. After $-0.28 actual earnings per share reported by OncoMed Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 10.71% negative EPS growth.

Since January 1, 0001, it had 0 insider purchases, and 5 insider sales for $27,111 activity.

Ratings analysis reveals 100% of OncoMed Pharma’s analysts are positive. Out of 2 Wall Street analysts rating OncoMed Pharma, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $16.0 while the high is $20.0. The stock’s average target of $18 is 486.32% above today’s ($3.07) share price. OMED was included in 2 notes of analysts from September 22, 2016. The rating was initiated by SunTrust with “Buy” on Tuesday, December 20. The company was initiated on Thursday, September 22 by H.C. Wainwright.

Iguana Healthcare Management Llc holds 0.88% of its portfolio in OncoMed Pharmaceuticals, Inc. for 350,000 shares. Perceptive Advisors Llc owns 1.04 million shares or 0.18% of their US portfolio. Moreover, Birchview Capital Lp has 0.07% invested in the company for 28,689 shares. The New York-based Cannell Peter B & Co Inc has invested 0.05% in the stock. Element Capital Management Llc, a New York-based fund reported 25,249 shares.

Investors sentiment increased to 1.41 in 2017 Q3. Its up 0.35, from 1.06 in 2017Q2. It improved, as 33 investors sold SPLK shares while 81 reduced holdings. 53 funds opened positions while 108 raised stakes. 143.10 million shares or 3.45% more from 138.32 million shares in 2017Q2 were reported. Glg Ltd Limited Liability Company reported 0.03% of its portfolio in Splunk Inc. (NASDAQ:SPLK). The New York-based Quantbot Lp has invested 0.02% in Splunk Inc. (NASDAQ:SPLK). Natixis has 0.02% invested in Splunk Inc. (NASDAQ:SPLK). Suntrust Banks Incorporated stated it has 5,241 shares. Marketfield Asset Management owns 33,311 shares for 0.58% of their portfolio. Alexandria Capital Llc reported 42 shares. Dupont Mgmt Corp holds 4,070 shares. Engineers Gate Manager LP holds 0.13% or 23,833 shares in its portfolio. Westfield Cap Management Lp reported 724,289 shares or 0.37% of all its holdings. Cibc Asset Mgmt Inc, Ontario – Canada-based fund reported 5,741 shares. Rhumbline Advisers owns 149,346 shares. Swiss Bancshares reported 510,000 shares or 0.04% of all its holdings. Walter And Keenan Finance Consulting Mi Adv invested 0.24% in Splunk Inc. (NASDAQ:SPLK). Us Bank De stated it has 176,457 shares. Japan-based Nomura Asset Mngmt has invested 0.02% in Splunk Inc. (NASDAQ:SPLK).

Since August 14, 2017, it had 0 insider purchases, and 16 sales for $33.06 million activity. 4,851 Splunk Inc. (NASDAQ:SPLK) shares with value of $390,684 were sold by STEIN LEONARD R. $7.75M worth of Splunk Inc. (NASDAQ:SPLK) shares were sold by SULLIVAN GODFREY. $380,665 worth of Splunk Inc. (NASDAQ:SPLK) was sold by St. Ledger Susan. Campione Richard sold 7,500 shares worth $598,350. Merritt Douglas sold $683,741 worth of Splunk Inc. (NASDAQ:SPLK) on Wednesday, September 13. CONTE DAVID F sold $694,980 worth of Splunk Inc. (NASDAQ:SPLK) on Friday, August 25. The insider Neustaetter Thomas M sold $244,668.

Among 43 analysts covering Splunk Inc (NASDAQ:SPLK), 34 have Buy rating, 0 Sell and 9 Hold. Therefore 79% are positive. Splunk Inc had 150 analyst reports since August 24, 2015 according to SRatingsIntel. The stock of Splunk Inc. (NASDAQ:SPLK) has “Outperform” rating given on Friday, August 19 by RBC Capital Markets. The stock has “Buy” rating by Stifel Nicolaus on Thursday, June 16. The rating was downgraded by Stifel Nicolaus on Friday, August 26 to “Hold”. The stock of Splunk Inc. (NASDAQ:SPLK) earned “Outperform” rating by BMO Capital Markets on Friday, August 25. As per Wednesday, February 3, the company rating was initiated by Maxim Group. The rating was upgraded by Barclays Capital on Monday, January 8 to “Overweight”. The firm has “Buy” rating by UBS given on Friday, November 17. Morgan Stanley maintained it with “Overweight” rating and $77 target in Friday, August 25 report. The firm has “Hold” rating given on Friday, November 17 by Stifel Nicolaus. On Friday, November 17 the stock rating was maintained by Credit Suisse with “Outperform”.

Fiera Capital Corp increased Pepsico Inc (NYSE:PEP) stake by 53,129 shares to 3.24M valued at $361.00 million in 2017Q3. It also upped Jpmorgan Chase & Co (AMJ) stake by 424,480 shares and now owns 578,811 shares. Canadian Natl Ry Co (NYSE:CNI) was raised too.

Analysts await Splunk Inc. (NASDAQ:SPLK) to report earnings on February, 22. They expect $-0.17 EPS, up 59.52% or $0.25 from last year’s $-0.42 per share. After $-0.39 actual EPS reported by Splunk Inc. for the previous quarter, Wall Street now forecasts -56.41% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>